Chimeric antigen receptor (CAR) polypeptides (and immune effector cells expressing the CARs) are provided comprising modified hinge domain sequences. Also provided are engineered antigen presenting cells (APCs) that express transgenes encoding target antigen and human leukocyte antigen (HLA). In further aspect, immune effector cells are provided that have been selected for elevated mitochondrial spare respiratory capacity.